Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.53 |
| ▸ | NPY1R | P25929 | 7/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.53 |
| ▸ | FNTA | P49354 | 8/20 | 0.46 |
| ▸ | FNTB | P49356 | 8/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30196815 | 0.92 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30531631 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31097734 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31097675 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31097735 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31097729 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31097681 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31097710 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31097683 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31752209 | 0.90 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085328-A1 | CONTROLLED EXPRESSION OF VIRAL PROTEINS | VOYAGER THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2024054983-A1 | CONTROLLED EXPRESSION OF VIRAL PROTEINS | VOYAGER THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085328-A1 | CONTROLLED EXPRESSION OF VIRAL PROTEINS | VAC14, GTF3C4, CRYZ | NPY4R 2340/4885NPY1R 3962/4885NPY2R 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.